Filed Pursuant to Rule 424(b)(5)
Registration No. 333-230723
PROSPECTUS SUPPLEMENT
(To
prospectus dated April 12, 2019)
3,369,564 Shares of Common Stock
Pre-Funded Warrants to Purchase 1,630,436 Shares of Common Stock
We are offering an aggregate of 3,369,564 shares of our common stock, par value $0.0001 per share, and, to certain investors in lieu
thereof, pre-funded warrants to purchase 1,630,436 shares of our common stock, or the Pre-Funded Warrants, in this offering.
The purchase price of each Pre-Funded Warrant equals the public offering price per share of common stock, minus $0.0001, and the exercise price of each Pre-Funded Warrant equals $0.0001 per share. The Pre-Funded Warrants are exercisable at any time, provided that each Pre-Funded Warrant holder will be prohibited from exercising such
Pre-Funded Warrants into shares of our common stock if, as a result of such exercise, the holder, together with its affiliates, would own more than 4.99% of the total number of shares of our common stock then
issued and outstanding, which percentage may change at the holders election to any other number less than or equal to 19.99% upon 61 days notice to us. This prospectus supplement also relates to the offering of the shares of our common
stock issuable upon exercise of such Pre-Funded Warrants.
Our common stock is currently listed on the Nasdaq Global Market
under the symbol ALT. On July 13, 2020, the last reported sale price of our common stock on the Nasdaq Global Market was $25.00. There is no established public market for the Pre-Funded
Warrants, and we do not intend to list the Pre-Funded Warrants on the Nasdaq Global Market, any other national securities exchange or any other nationally recognized trading system.
Investing in our common stock involves a high degree of risk. You should review carefully the risks and uncertainties described under the heading Risk
Factors on page S-10 of this prospectus supplement, and under similar headings in the documents that are incorporated by reference into this prospectus supplement and the accompanying prospectus.
Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities, or passed upon the
adequacy or accuracy of this prospectus supplement and the accompanying prospectus. Any representation to the contrary is a criminal offense.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
PER SHARE
|
|
|
PER
PRE-FUNDED
WARRANT
|
|
|
TOTAL
|
|
Public Offering Price
|
|
$
|
23.00
|
|
|
$
|
22.999
|
|
|
$
|
114,999,837
|
|
Underwriting Discounts and Commissions (1)
|
|
$
|
1.38
|
|
|
$
|
1.38
|
|
|
$
|
6,900,000
|
|
Proceeds to Altimmune (before expenses)
|
|
$
|
21.62
|
|
|
$
|
21.619
|
|
|
$
|
108,099,837
|
|
(1)
|
|
See Underwriting for a description of compensation payable to the underwriters.
|
We have granted the
underwriters an option for a period of 30 days to purchase up to an additional 750,000 shares of our common stock from us at the public offering price, less underwriting discounts and commissions. If the underwriters exercise the option in full, the
total underwriting discounts and commissions payable by us will be $7,935,000 and the total proceeds to us, before expenses, will be $124.3 million.
Delivery of the
shares of common stock and Pre-Funded Warrants is expected to be made on or about July 16, 2020.
Joint
Book-Running Managers
|
|
|
|
|
|
|
|
Jefferies
|
|
Evercore ISI
|
|
Piper Sandler
|
Co-Manager
Roth Capital Partners
Prospectus Supplement
dated July 13, 2020.